Denali Stock Analysis

Denali Stock Analysis Notes

About 15.0% of the company shares are held by company insiders. The book value of Denali Therapeutics was currently reported as 8.64. The company recorded a loss per share of 1.07. Denali Therapeutics had not issued any dividends in recent years. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about Denali Therapeutics call Ryan Watts at 650 866 8548 or check out https://www.denalitherapeutics.com.

Denali Therapeutics Investment Alerts

Denali Therapeutics Upcoming and Recent Events

Denali Largest EPS Surprises

View All Earnings Estimates

Denali Therapeutics SEC Filings

Denali Therapeutics Thematic Classifications

Denali Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Denali Therapeutics's market, we take the total number of its shares issued and multiply it by Denali Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Denali Profitablity

The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.48) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.48.

Management Efficiency

Denali Therapeutics has return on total asset (ROA) of (0.0785) % which means that it has lost $0.0785 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.124) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -36.68. The current Return on Average Assets is estimated to decrease to -0.27. Denali Therapeutics Net Current Assets as percentage of Total Assets are decreasing as compared to previous years. The last year's value of Net Current Assets as percentage of Total Assets was reported at 69.06. The current Asset Turnover is estimated to increase to 0.10, while Total Assets are projected to decrease to under 1.2 B.

Technical Drivers

As of the 26th of September, Denali Therapeutics shows the Standard Deviation of 1.95, mean deviation of 1.52, and Variance of 3.81. Denali Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Denali Therapeutics, which can be compared to its rivals. Please confirm Denali Therapeutics variance and value at risk to decide if Denali Therapeutics is priced favorably, providing market reflects its regular price of 21.39 per share. Given that Denali Therapeutics has information ratio of (0.22), we urge you to verify Denali Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Denali Therapeutics Price Movement Analysis

Denali Therapeutics Insider Trading Activities

Denali Therapeutics Technical and Predictive Indicators

Denali Therapeutics Forecast Models

Denali Therapeutics' time-series forecasting models are one of many Denali Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Denali Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Denali Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Denali shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Denali Therapeutics. By using and applying Denali Stock analysis, traders can create a robust methodology for identifying Denali entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Denali analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Denali analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Denali Therapeutics stock analysis indicators help investors evaluate how Denali Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Denali Therapeutics shares will generate the highest return on investment. By understating and applying Denali Therapeutics stock analysis, traders can identify Denali Therapeutics position entry and exit signals to maximize returns.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in inflation. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.

Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.